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Abstract 
ncRNAs are emerging as key regulators of physiological and pathological processes and therefore 
have been identified as pharmacological targets and as markers for some diseases. 
Oligonucleotide analogues represent so far the most widely employed tool for the modulation of 
the expression of ncRNAs. In this perspective we briefly describe most of the known classes of 
ncRNAs and then we discuss the design and the applications of oligonucleotide analogues for their 
targeting. The effect of modifications of the chemical structure of the oligonucleotides on 
properties such as the binding affinity toward  targets and off targets,  stability to degradation and 
on their biological effect (when known) are discussed. Examples of molecules currently used in 
clinical trials are also reported. 
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Introduction 
Since the discovery that small non-coding RNAs (ncRNAs) regulate gene expression, being involved 
in physiological and pathological processes, our knowledge on non-coding RNAs has grown 
enormously
1
. Non-coding RNAs represent the largest part of the transcribed genome, with lengths 
ranging from a few tens to several thousands of bases. The main effort of scientists is to 
understand their function, the role they have in diseases and the eventual networks they are 
involved in. Computational and experimental strategies led to the prediction and identification of 
ncRNAs, yielding  a number of databases (noncode, miRbase, lncRNAdb, 
NONCODE, LncRNADisease ), which represent a valuable tool to approach the complex world of 
ncRNAs
2
.  The fact that many ncRNAs regulate gene expression renders them ideal  
pharmacological targets. In principle we may either promote the expression of any gene which is 
deficient in a pathological situation as tumor suppressors and transcription factors or inhibit the 
expression of undesired genes by modulating the expression of the related ncRNA. In this context 
molecules such as antagomiRs, or mimics of microRNAs (miRNAs or miRs), which affect the 
function of miRNA or antagoNAT, which block the Natural Antisense Transcripts, have been 
explored. The relationships found between the alteration of expression of ncRNAs and diseases 
allowed the identification of ncRNAs as new biomarkers for specific diseases. Several studies have 
been reported so far on the modulation of ncRNAs’ function  by oligonucleotides,  oligonucleotide 
analogues and small molecules; few molecules are currently being used in clinical trials. 
In this perspective we will first describe a large part of the known  classes of ncRNAs (grouped 
based on their length), with an emphasis on those molecules involved in diseases. We will then 
discuss the current strategies in designing ncRNAs-targeting therapeutics, as well as the associated 
challenges.  
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Short ncRNAs  
We will describe, among the small ncRNAs,  molecules composed of  ≈ 18-200 bases  (summarized 
in Table 1). Most of these molecules play key roles in the transcription of genes (small interfering 
RNAs, micro RNAs, small viral RNAs, transcription initiation RNAs), others are involved in post- 
transcriptional gene silencing (mirtrons, microRNA-offset RNAs).  
Small interfering RNAs (siRNAs), are small double stranded RNAs (dsRNAs),  20-24 nucleotides 
(nts) long that are  processed from longer dsRNAs by the endonuclease Dicer. siRNAs can originate 
from transposons, heterochromatic sequences, intergenic regions, long-RNAs, and messenger 
RNAs (mRNAs). First discovered in plants
3
, they were successively detected in flies and found to be 
ubiquitous in eucaryotes
4
. siRNAs  are the main actors of RNA interference (RNAi), a natural 
cellular process which mediates the silencing of homologous transcripts through the full 
complementarity of siRNAs and target mRNAs, providing an innate defense mechanism against 
invading viruses and ensuring genome integrity via transcriptional silencing of undesired genomic 
loci (e.g. retrotransposons or repeat sequences)
5
.  
A widely studied class of small ncRNAs is represented by microRNAs, miRNAs, whose involvement 
in several human diseases has been intensively investigated.  miRNAs are generated from longer 
precursors, pre-miRNAs, which are loaded and processed by the miR loading complex (miRLC) 
formed by Ago2, responsible for the loading and unwinding of the duplexes, and Dicer which 
cleaves the precursor into a smaller fragment
6
. Maturation of miRNAs may also occur through a 
different pathway not including Dicer: premiRs beginning with 5’U or 5’A are part of the miRNA 
precursor deposit complex (miDPC), in which Ago2 cleaves  the precursors and binds the mature 
miRNAs
7
. 
The mature miRNAs are 19- to 21-nts in  length, they mediate silencing of  gene expression 
Page 3 of 76
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
through  the imperfect  binding to the 3’ untranslated region (3’ UTR) or  the 5’ UTR of protein-
coding genes  and cause translational repression
8
. In addition, they can function as positive  
regulators of gene expression by  increasing  the translation of a target mRNA through recruiting 
protein complexes, such as Argonaute 2 (AGO2) and fragile X mental retardation syndrome related 
protein 1 (FXR1), and indirectly  up-regulating  the translation of a target gene
9
. Deregulation of 
the expression of miRNAs has been found in a very large number of diseases, from cancer to 
cardiac failure, to metabolic disorders. Some cases will be discussed in the next paragraphs. 
Mirtrons are short hairpin introns that use an alternative miRNA biogenesis pathway for their 
maturation:  these short hairpin introns are in fact excised by the intron pathway before being 
cleaved by Dicer into a  mature form of  ~22 nts. They are indistinguishable from the typical 
miRNAs and  some of them  are evolutionarily conserved across similar species
10
. Mirtrons appear 
particularly susceptible to epigenetic regulation in some diseases like bladder cancer and  in acute 
lymphoblastic leukemia
11
.  
MicroRNA-offset RNAs (moRNAs) originate  prevalently  from the 5’ arm of miRNAs hairpin 
precursors; in their mature form they are 20 nts long . This suggests that the biogenesis of 
moRNAs and miRNAs might be linked, but not interdependent. The expression levels of moRNAs 
seem to be regulated in different developmental stages of Ciona intestinalis. Recently they have 
also been identified in humans and in herpes virus, but their biogenesis and possible functions 
remain to be determined
12
. Furthermore, some weakly expressed moRNAs have been found in 
solid tumors, together with other small RNAs
13
 .  
Small nucleolar RNAs (snoRNAs) of 60-300 bases are mainly found in the nucleolus; in mammals 
they are hosted in the introns of genes both coding for proteins and non-coding.  They work as 
guide RNAs in the post-transcriptional modification of ribosomal and spliceosomal RNAs
14
; 
hybridization of the ribosomal RNA (rRNA) by snoRNAs is followed by the rRNA modifications (2’-O 
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ribose methylation or pseudouridylation) by specific proteins which associate to form the snoRNP 
complexes. SnoRNAs were hypothesized also to be precursors of miRNAs
15
. Several lines of 
evidence link mis-regulation of snoRNAs to cancer development
16
. Moreover, a loss in the 
expression of the snoRNA C/D box HBII was associated with the onset of the Prader Will 
syndrome
17
. Another family of ncRNAs is represented by the PIWI-interacting RNAs (piRNAs), 
oligomers of 26-31 nucleotides containing a 2’-OMe at their 3’ end, originally named repeat 
associated small interfering RNAs (rasiRNAs)
18
. Unlike miRNAs, piRNAs do not require Dicer for 
their maturation and do not have a  predicted hairpin structure. PiRNAs  bind the PIWI proteins, a 
subfamily of the Argonaute family of proteins, while miRNAs interact with Ago.  They play a key 
role in gametogenesis, heterochromatin modification and germline transposon silencing. Genome 
mapping of these small RNAs revealed that despite the extremely high diversity of piRNAs, they 
are localized  in a  relatively small number of genomic regions called piRNA clusters. PiRNA clusters 
were found to be bi-directionally transcribed as long primary transcripts. They are localized 
intergenic or in gene desert regions, and some piRNAs have recently been localized in the 3’UTR of 
protein coding genes. Several independent studies indicate  that the piRNAs are involved in cancer 
development with oncogenic or tumor suppressor roles: the expression  of piR-Hep1 was  found  
up-regulated in hepatocellular carcinoma
19
,  while the level of piR-823 in gastric cancer tissues was  
significantly lower compared to normal tissues
20
 . 
Small-viral RNAs (svRNAs), are composed by 22–27 nts, are derived from viruses and  can control 
the viral switch between transcription and replication. In particular, svRNAs are detectable during 
replication of various influenza A viruses and  their expression correlates with the accumulation of 
viral genomic RNA (vRNA)
21
.  
Transcription initiation RNAs (tiRNAs) are 18 nts tiny RNAs,  localized into the nucleus and derived 
from sequences immediately downstream of the RNA polymerase II transcription start sites in 
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animals. They are generally associated with highly expressed genes and with G+C-rich promoters, 
bind to transcription-factors. Although the exact role of these molecules in the control of  gene 
expression is poorly understood and their involvement in diseases at present is mostly unknown, 
their importance is generally recognized
22
.  
 The Promoter-associated small RNAs (PASRs) of 26-50 nts are short transcripts localized in the 
promoter regions, identified in H. sapiens and belonging to the small ncRNAs.  Transcription start 
site–associated  RNAs (TSSa-RNAs), originally identified in M. musculus, are 20-90 nts long, flank 
active promoters
23
 and have been hypothesized to regulate transcription; they are probably 
produced during the synthesis or degradation of longer upstream antisense RNAs (uaRNAs)
24
. 
Other small silencing RNAs that bind protein members of the Argonaute family are: QDE-2 
interacting small RNAs (qiRNAs)  about 20-21 nucleotides long, involved in the DNA damage 
response; telomere small RNAs ( tel-sRNAs) of approximately 24 nucleotides, engaged in telomere 
maintenance; Sno-derived RNAs (sdRNAs)  which are predominantly 20–24 nts  in length and 
modulate RNA silencing; splice junction associated RNAs (spliRNAs) 17- to 18-nucleotides long,  
involved in the post transcriptional gene silencing. 
Long ncRNAs 
Long non coding RNAs (lncRNAs) represent the largest and most heterogeneous class of ncRNAs, 
arbitrarily defined as being longer than 200 nucleotides (Table 2). They constitute a significant 
fraction of  mammalian transcriptome, whose biological role is now being discovered. The 
observation that more sophisticated organisms tend to have a higher number of non-coding RNAs 
renders investigations on lncRNAs even more challenging. Identification of such sequences, 
complicated by the fact that some lncRNAs contain short protein-like subsequences or long 
putative ORF, is carried out by RNA sequencing techniques and by bioinformatic tools. Recently a 
new  tool to distinguish coding and non-coding RNA sequences has been reported and named 
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CNCI
25
; this tool classifies RNA sequences based only on their composition, allowing the 
annotation of lncRNAs for species lacking a whole or precise  genome annotation.  LncRNAs have 
been localized in inter and intragenic sequences, have been found both in the nucleus and in the 
cytoplasm, possess diverse functions and may act either in cis or in trans. Some long non coding 
RNAs have been demonstrated to interact with proteins (as transcription factors, PRC2), while 
others interact with oligonucleotides (mRNA or miRNA). Most of these lncRNAs are transcribed by 
RNA polymerase II,  polyadenylated and expressed at low levels as compared to protein-coding 
genes. Predominantly lncRNAs have been found to be involved in the modulation of mRNA 
transcription, processing and in the modulation of the regulatory pathways at the post-
transcriptional level
26
. In addition, lncRNAs have been shown to play a role in cell-cell signaling and 
in the organization of protein complexes. 
Several lines of evidence indicate that there are essentially two modes of action through which  
lncRNAs exert their function: in cis- and trans. Cis-acting lncRNAs control the expression of genes 
located close (or sometimes far) to their transcription sites on the same chromosome, whereas 
trans-acting lncRNAs can either repress or activate gene expression at independent loci
27
.  
Recently, loss-of-function experiments have been used to investigate cis- versus trans-effects of 
long intergenic non coding RNAs (lincRNAs). These studies suggest that most of the lincRNAs 
identified and characterized so far act as trans-regulators
28
, although some cis-regulators have 
been identified 
27b, 28c, 29
. However, for both classes of lncRNAs, the targeting mechanism is still far 
from being understood completely. 
Follows a brief description of a small number of lncRNAs. 
 X-inactive specific transcript RNA (Xist) is one of the first ncRNAs discovered
30
, about 19 kb long in 
humans, with an intrinsic cis-regulatory capacity. It can function while remaining tethered to its 
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own locus  by binding the Polycomb repressive complex 2 (PRC2), which is responsible for histone 
trimethylation at lys27,  induces the formation of inactive heterochromatin on the X chromosome 
from which it is transcribed, with consequent initiation of inactivation of X-chromosome
31
. Xist is 
either positively or negatively regulated by other lncRNAs; alteration in the expression of Xist has 
been demonstrated to contribute to tumorigenesis. Loss of Xist after X chromosome inactivation 
results in the reactivation of X-linked genes, which promote tumorigenesis
32
. Other examples of 
lncRNAs regulating transcription after association with histone modifying complexes are 
represented by the Hox antisense intergenic RNA (HOTAIR), the antisense noncoding RNA in the 
INK4 locus (ANRIL) and the KCNQ1 overlapping transcript 1 (KCNQ1OT1) 
28b
.  lncRNAs have also 
been found to show enhancer-like activity (eRNA)
33
. These  lncRNAs, ≈2- kb in length,  are mostly  
not polyadenylated. Their expression correlates positively with the accumulation of transcripts at 
the neighbour promoter, suggesting that they are involved in the activation of the synthesis of 
mRNA. eRNAs have been found in different species, with ≈2000 being identified in mouse and 
3000 in humans, suggesting an extensive  mechanism of gene regulation. Unlike the known 
enhancer molecules that are embedded in a DNA sequence, eRNAs are able to move around in the 
nucleus. Thus, they are also capable of modulating genes whose positions are far away on the DNA 
strand; recent studies suggest that the eRNAs are critical regulators of differentiation and 
development
34
.  
Regulation of the mRNA processing may occur through splicing modulation by the natural 
antisense transcripts (NATs) and the metastasis associated lung adenocarcinoma transcript 1 
(MALAT1). NATs are phylogenetically conserved transcripts, with lengths ranging from few tens to 
few thousand of base pairs, expressed at very low levels
35
. They modulate the expression of their 
cognate sense transcripts, stabilizing the protein coding sense transcript. Many functions have 
been hypothesized for NATs, ranging from epigenetic regulation of transcription, chromatin 
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modifications and monoallelic expression; these functions seem to be exploited through 
interactions of the NATs with DNA and chromatin. An alteration in the levels of expression of NATs 
has been demonstrated to be associated to different diseases:  NATs have been identified in the 
Huntington disease repeat locus
36
, in the brain derived neurotrophic factor
37
 and in the 
apolipoprotein 1
38
.    
MALAT1, also known as nuclear-enriched abundant transcript 2 (NEAT2), is a very conserved 
ncRNA, retained in the nucleus, originally identified as a prognostic marker for metastasis and 
patient survival in lung adenocarcinoma
39
. Loss of function studies revealed that MALAT1 
regulates the expression of genes associated to metastasis; in particular it suppresses  inhibitors 
while activating promoter of metastasis
40
. 
Ultraconserved RNAs (T- UCRs) are lncRNAs characterized by a high degree of conservation within 
different species (ranging from rats, dogs to humans)
 41
. They have been found in intra and inter-
genic regions, are expressed in normal tissues and have also been associated to the pathogenesis 
of cancer
42
. These lncRNAs  have been hypothesized to guide the RNA editing processes and to 
regulate post transcriptional events through the association to the 5’ end or to the 3’ UTR of a 
mRNA and the binding to miRNAs or to targets of miRNAs. 
Some lncRNAs have also been found in the cytoplasm, where they bind to their partner by 
sequence complementarity. Competing endogenous RNAs (ceRNAs), also known as miRNA 
sponges, are an example of cytoplasmatic RNAs acting as  inhibitors of miRNAs. They have recently 
been demonstrated to participate to physiological processes as cell differentiation and 
pathological processes as tumorigenesis
43
. The understanding of the role of lncRNAs as 
endogenous microRNA sponges has been recently enriched by the discovery of a new class of 
lncRNAs, called circular RNAs (circRNAs).   The majority of circRNAs arise from  a 3′–5′ ligation of 
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both ends of a linear RNA strand.  An extraordinary example is the circRNA CDR1 (also known as 
ciRS-7) a ~1,500-nucleotide-long circRNA, which is predominantly expressed in the human and 
mouse brain, that contains more than 70 binding sites for miR-7
44
 .  
Other examples of lncRNAs include the Promoter upstream transcripts (PROMPTs) with a length of 
200-600 nts, 
45
 produced upstream of protein coding genes, present in the nucleus and quickly 
turned over by the RNA exosome. PROMPTs are capped at 5’ and polyadenilated at 3’ end (pA 
signals are linked to degradation)
46
. No relation has been found with cancer yet. 
 
Targeting ncRNAs by oligonucleotides and analogues 
The number of ncRNAs with known functions is steadily increasing and in the  last decade ncRNAs 
have come to represent an exciting avenue for the treatment of diseases
47
. By identifying and 
characterizing ncRNAs, it may be possible to manipulate the expression of a therapeutic gene for a 
range of indications. It is clear that the development of drugs able to modulate in a specific fashion 
the expression and function of ncRNAs represents an intriguing challenge, as it poses several 
issues related to the efficient delivery of the drugs to the targets, toxicity of the molecules, off 
target effects  and last but not least cost of production. It is worthwhile highlighting that, thanks to 
the efforts carried out so far by the scientific community and pharmaceutical companies, some 
molecules are in clinical trials for the cure of cancer, HCV and heart failure. Most of the studies 
published so far refer to the gene silencing and to the interference in maturation or function of 
miRNAs (Figures 1 and 2), but in the last few years the interest toward regulators of the  
expression of lncRNAs has increased. Two approaches have been reported to modify production 
and function of ncRNAs: one is based on the use of small molecules, the other is based on the use 
of oligonucleotides and analogues.  
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Small molecules-based drugs usually interfere in the interactions of ncRNAs with proteins or DNA; 
they are derived from screenings of large libraries or are based on aminoglycosides showing 
structural and/or electrostatic complementarity to their RNA targets. Examples of small molecules 
as modulators of the functions of ncRNAs are so far restricted to inhibitors of the maturation of 
miRNAs. The second strategy, by far the most investigated, is based on the use of oligonucleotides 
(ONs),  synthetic or expressed, or oligonucleotide analogues which bind for complementarity their 
targets. Standard oligonucleotides are not the perfect molecules for sequence-specific recognition 
of targets, as their binding affinity inversely correlates with their binding specificity. For this reason 
oligonucleotide analogues as Locked Nucleic Acids (LNAs) or Peptide Nucleic Acids (PNAs), showing 
a kinetically controlled selectivity against single-mismatch binding are currently being 
investigated
48
.  The use of oligonucleotide analogues as LNAs, morpholinos, 2’-O-Methyl-RNAs (2’-
OMe), phosphorothioates and combinations of them  is actually preferred to the use of natural 
oligonucleotides, also due to their higher resistance to degradation in vivo.  Follows a brief 
description of the properties of synthetic oligonucleotides analogues, which have been explored 
so far as tool to alter the functions of ncRNAs. Approaches for the modulation of the expression of 
ncRNAs are reported in Tables 3-7. 
Modified oligonucleotides  
The oligonucleotide analogues currently employed to regulate the expression of ncRNAs were 
originally developed as antisense or antigene agents, to overcome the stability and specificity 
drawbacks of standard oligonucleotides. Here, we discuss how the modifications affect the 
structure, the stability to degradation, the affinity towards the targets of these analogues. We will 
focus on analogues which find applications as modulators of the expression and function of 
ncRNAs. A very large variety of analogues has been explored, with modifications to the sugar-
phosphate backbone or to the bases (Figure 3 and 4); those who have shown promising features 
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as drugs carry modification on the sugar-phosphate backbone and include molecules with a 
charged phosphate backbone as  LNA, 2’-OMe, 2’-O-(2-methoxyethyl) RNAs (2’-MOE), 2'-deoxy-2' 
fluoro RNAs (2’-F) , and molecules with a neutral backbone as morpholinos and PNAs. Modified 
nucleotide bases have been explored in the context of siRNAs. Finally, a different strategy to 
protect oligonucleotides from degradation consists in the capping of the oligonucleotide 5’ or 3’ 
end (Figure 5); examples of such modifications are discussed in the paragraphs concerning the 
inhibition of miRNAs, the replacement of miRNAs and the gene silencing. 
The first generation of antisense compounds based on oligonucleotide analogues includes the so-
called phosphorothioate (PS) oligonucleotides, in which a sulfur atom replaces one oxygen atom in 
the phosphodiester bond. This substitution renders the P atom chiral, therefore oligonucleotide 
sequences containing n nucleotides and n-1 PS linkages, have 2
n-1 
diastereoisomers. This fact might 
have implications on the activity of the molecules as in principle many similar species may have 
different biological targets.
49
 The introduction of a PS linkage results in a greater resistance against 
endonucleases but causes a slight reduction of the binding affinity towards the RNA target. 
Stability studies carried out on  PS-mRNA heteroduplexes showed that the melting temperature 
decreased by almost 0.5°C per nucleotide, with respect to that recorded for standard 
phosphodiester DNA/RNA duplexes
50
.  Nevertheless PS analogues are still widely used as antisense 
agents and also in strategies aimed at interfering with the expression of ncRNAs; in fact the 
inclusion of a PS linkage improves the pharmacokinetic properties of the ON by promoting its 
binding to serum proteins and increasing its in vivo half-life. 
51
 Interestingly, some 
phosphorothioate oligonucleotides reached the market; this is the case of the vitravene 
(fomirvsen) commercialized by Isis Pharmaceuticals for the treatment of cytomegalovirus 
retinitis
52
.  
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The second generation of analogues, obtained  to overcome the relatively low affinity of 
phosphorothioate oligonucleotides toward the complementary RNAs, is characterized by 
modifications at the   2'-position of the ribose. Introduction of substituents in the 2’ position of the 
sugar affects the conformation of the sugar and therefore the binding affinity of the modified 
strand toward its complementary. The conformations assumed by sugars are defined by the 
dihedral angles of the sugar ring as C3’-endo, C2’-exo (or North), assumed by sugars in A-form 
dsRNA, and C2’-endo, C3’-exo (South) typical of sugars in B-form ds DNA (Figure 6). Examples of 2’ 
modified oligonucleotides are represented by 2’-MOE and 2’-OMe RNAs, showing an enhanced 
affinity toward complementary RNAs and also an enhanced stability to degradation as compared 
to  2’-deoxy and RNA oligonucleotides 
53
. 2’- MOE-modified oligonucleotides have higher affinity 
and specificity to RNA than their 2’-OMe analogs
54
. The analysis of the crystal structure of a 2’-
OMe RNA duplex suggests that this modified RNA arranges in a A-type RNA helix, with some 
deviations with respect to the canonical RNA structure consisting in a low base pair rise,  elevated 
helical twist and inclination angles
55
. The ring of 2’-OMe sugars  is found preferentially in the 
North conformation, and the 2’-OMe groups point toward the minor groove of the duplex; distinct 
hydration patterns, found in the major and minor groove, were supposed to play a structural role. 
The X-ray structure solved for a 2’- MOE RNA/RNA duplex revealed  a conformational 
preorganization of the MOE substituents: all the modified riboses have a C3’-endo (North) 
conformation, and this is likely the reason of the high binding affinity and also of the extensive 
hydration of the substituents. The hydration pattern connecting the substituents and the oxygen 
atoms of the phosphate in the minor groove of 2’-MOE RNA has been hypothesized to contribute 
to the 2’-MOE resistance to nucleases
56
. Both 2’-OMe and 2’-MOE have been tested in different 
experimental contexts,  both in vitro and in vivo; they have an elimination half-life of 25–30 days in 
all organs and species studied
57
.    
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  2’-F nucleotides are another example of 2’ modified RNAs. It was observed that the substitution 
in 2’ position of a hydroxyl group by a fluorine atom does not imply a substantial change in the 
conformation and in other structural features of the sugar. The increase in the binding affinity 
toward RNA complementary sequences has been explained with enhanced base-pairing and 
stacking interactions due to the electronegative fluorine atom
58
. The absence of the hydroxyl 
group in these molecules confers greater stability to chemical hydrolysis and high pH as well as an 
increased resistance against ribonucleases, leading to a higher survival in a biological environment, 
compared to the natural counterparts. An example of successful application of 2’-F analogues is 
represented by Macugen (pegaptanib), an RNA aptamer with  2'-F pyrimidine rings,  approved by 
the U.S. Food and Drug Administration, that selectively antagonizes with VEGF and is currently 
clinically employed  for the treatment of exudative (wet) age-related macular degeneration
59
.  
Morrissey and co-workers have recently shown that the combined use of 2'-F pyrimidine with 2'-
OMe purine encapsulated in liposomes yields RNA duplexes with high stability in serum and 
improved activity in vivo
60
. Furthermore, phosphorothioate and phosphodiester analogues with 
2'F-2’-deoxynucleosides were synthesized and used for antisense applications  and ribozymes as 
they appear to adopt the most suitable form to interact with target proteins 
61
. Between the other 
groups introduced  at the 2’ position of ribose we also mention the allyl or the more hindered 
groups, as benzyl and 4-methylpyridine
62
. 
2’-modified RNAs have been applied as inhibitors of the function and biogenesis of miRNAs. 
Locked nucleic acids (LNAs) are a distinctive class of modified oligonucleotides containing a 
methylene bridge, which connects the 2’-O with 4’-C of the ribose, to form a rigid bicycle, locked 
into a C3’-endo (North) sugar conformation. The ability of LNA monomers to twist the sugar 
conformation from a South-type to North-type when introduced into an oligonucleotide sequence  
leads to the formation of  thermodynamically more stable duplexes and results in a more effective 
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biological activity.  LNA oligonucleotides possess a binding affinity towards the target molecules 
higher than that of the natural counterparts and this is reflected in an increase in melting 
temperature of LNA hybrids of about 8 °C per included  LNA monomer
63
. Structural investigations 
by NMR and X-ray crystallography performed on different LNA-RNA and LNA-DNA heteroduplexes 
demonstrated that the LNA-modified oligonucleotides adopt a perfectly A-type duplex form very 
similar to that adopted by the natural duplexes
64
. Furthermore, LNAs display excellent mismatch 
discrimination, resistance to enzymes and show a serum decay and a tissue distribution similar to 
that of phosphorothioate oligonucleotides
57
. LNA oligomers and mixed LNA/DNA oligomers are 
commonly employed to target natural oligonucleotides as antisense and siRNA agents 
65, 66
.  
Several applications of LNA as antagomiRs are also reported. 
Combination of 2’-OMe, 2’-MOE, 2’-F, LNA with the phosphorothioate backbone represents the 
latest frontier in the field of oligonucleotide analogues as drugs
67
. 
Between the analogues with a constrained backbone, we also report the 2’, 4’ constrained 2’-O-
ethyl modified cEt 
68
; the sugar adopts a C3’-endo pucker, thus  cEt modified monomers confer an  
improved  thermal stability to duplexes in a way which is comparable to LNAs. Also the stability to 
nucleases is higher than that found for LNAs and 2’-MOEs. Experiments in which  cEt modified 
oligonucleotides were tested as antisense in animals demonstrate that they possess an enhanced 
potency and therapeutic profile
69
.  cEt modified oligonucleotides have been employed for the 
knockdown of the lncRNA MALAT1. 
Other examples of analogues are those with modifications only at the 4’ position of the sugar ring: 
replacement of the oxygen by a sulfur atom as in 4’-thio-modified RNAs (4’S-RNA) results in an 
increase of the stability to nucleases
70
; combinations of 4’-thioribose and 2’-ribose modifications, 
as in 4’S-FANA, provide molecules with an enhanced plasma stability and siRNA activity
71
.  
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Last but not least we will briefly describe oligonucleotide analogues lacking sugars on the 
backbone, as morpholinos and Peptide Nucleic Acids.  
Morpholino oligonucleotides (MO) were synthesized by replacing the riboside backbone with a 
morpholinic moiety and the phosphodiester intersubunit linkage with a phosphoroamidate linker. 
The neutral backbone confers to this molecule a high binding affinity for complementary DNAs or 
RNAs and good enzymatic stability, also showing excellent solubility properties. Since  morpholino 
oligonucleotides are not recognized even by signaling proteins, they have been applied very 
effectively for the inhibition of the RNA function by blocking its translation
72
, redirection of 
splicing
73
 and more recently as specific splice switching agents to alter the processing of pre-
miRNAs 
74
.  The low toxicity and good uptake granted morpholino oligos an extensive use in the 
knockdown of target gene expression in developing zebrafish
74
. 
Other synthetic oligonucleotide analogues are PNAs, in which the naturally occurring sugar-
phosphate backbone has been replaced by N-(2 - aminoethyl)-glycine units. A methylene carbonyl 
linker connects natural as well as unusual (in some cases) nucleotide bases to the secondary amine 
of the backbone 
75
 . Binding to complementary DNA, RNA and PNA oligomers occurs in a sequence 
specific fashion and also with a high affinity obeying to the Watson-Crick rules. Unlike DNA and 
RNA, PNA recognizes and binds complementary strands in both parallel and antiparallel 
orientations. However, the antiparallel orientation  was found to be more stable.  Although the  
chemical structure of PNAs is totally different from that of natural nucleic acids, the 
hybridization properties  are not only preserved, but improved for PNAs . The  uncharged scaffold 
of PNAs enhances thermal stability of PNA-RNA (PNA-DNA) duplexes and enables PNAs to form 
stable hybrids also in low-salt conditions 
76
.  For the inhibition of gene expression they appear to 
be more effective than other antisense molecules; because of their neutral backbone they are able 
to invade local RNA secondary structures, overcoming the issue related to the accessibility of RNA. 
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Application of PNAs as drugs is hampered by their low cellular uptake which can be improved by 
the conjugation to carrier peptides or by further modification of the backbone, to introduce 
charges
77
. The use of PNAs as inhibitors of the biogenesis of miRNAs and as antagomiRs is 
described. 
Modifications can also be introduced in the bases; in this context a large amount of work has been 
carried out on modified siRNAs
78
 . Examples of modified bases include 2-thiouracil and 
pseudouracil, characterized by a C3’-endo sugar pucker, 2,4 difluorotoluene and 2,6 diamino 
purine, in which the hydrogen bond pattern with the complementary base is modified and also 
bases with hindered substituents, as propyl and cyclopentyl on the bases which affect the ability 
of oligonucleotides to interact with proteins.  
The application of oligonucleotides as drugs is still limited by the toxic effects deriving by their 
accumulation in the liver and kidney. We have to say that the toxicity of oligonucleotide analogues 
seems to be a function of the experimental system tested: experiments carried out in zebrafish 
demonstrated that LNA and 2’-OMe analogues are toxic to this organisms, unlike morpholinos
79
. In 
addition controversial data can be found in the literature: in experiments carried out in mice, 
some oligonucleotides bearing LNAs were reported to increase the serum levels of alanine-
aminotransferase (ALT), which is a marker of hepatocellular injury, while other examples show no 
dose-limiting toxicity in preclinical and clinical studies
67b, 80
. A prediction of the toxicity of such 
molecules based on the nucleotide sequence, type and position of the modification is not possible 
yet, due to the lack of Structure-Activity-Relationship studies for the molecules tested in pre-
clinical and clinical trials. An effort in this direction is represented by the work of Hagedom et al, 
reporting an analysis of the hepatotoxic potential of phosphorothioate LNAs carried out by an 
ensemble of biochemical and histopathological studies on mice,  statistical modeling and sequence 
analysis
81
. The authors demonstrate that machine learning techniques may be employed to relate 
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chemical features (modification and sequence) to the hepatotoxic potential of the modified 
oligonucleotides. 
Another critical point for the therapeutic application of oligonucleotides is represented by their 
delivery. Efficient delivery of naked oligonucleotides has been demonstrated in vivo in few cases, 
for example for LNAs targeting miR-122 in non-human primates
82
.  In most cases, the 
internalization of standard oligonucleotides is very poor and the efficiency of the oligo-based drug 
is limited by its rapid degradation. A large variety of delivery systems has been explored so far, 
ranging from peptides to liposomes, to nanoparticles
83
. The delivery systems have a dual function: 
drive the oligonucleotides to their target and protect them from degradation. Many delivery 
systems are optimized to increase the uptake of charged molecules; they are based on cationic 
lipids variously decorated with PEG, PEG-PLA, or PEG grafted with ligands which recognize specific 
receptors or antigens overexpressed on the surface of the cell
84
. In these cases the interactions 
between the oligonucleotides and the cargo are mainly electrostatic. Use of ligands conjugated to 
the termini of oligonucleotides as N-acetyl galactosamine  and folate has been reported. 
 A different strategy is applied for the delivery of uncharged oligonucleotide analogues: in this case 
cargos are usually covalently linked to one end of the oligo. Peptides as polyarginine, Tat, Nuclear 
Localization Signals have been employed in different cases; we have to recognize that for 
molecules as PNAs there is not yet a general approach for delivery , as the efficiency of the uptake 
seems to be cell dependent
85
.   
Strategies for the inhibition  of maturation of miRNAs 
 Different strategies to inhibit the maturation of miRNAs have been explored; one is based on 
molecules targeting precursors of miRNAs (pre-miRs and pri-miRs) such as small molecules and 
synthetic oligonucleotide analogues.  
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These studies are still in their infancy and in fact, as far as we know, despite the number of 
published papers, no clinical trial has been reported yet on molecules which inhibit the maturation 
of miRNAs 
86
. A recent paper demonstrates that antagomiRs affect the maturation miRNAs too
87
. 
Small molecules have been identified by random screening of libraries or  after  testing 
aminoglycosides for the targeting of pre-miRs
88
; one striking example is represented by 
streptomycin which has been demonstrated to selectively  inhibit miR-21 in living cells
89
.  
Inhibition of the maturation of miRNAs has been achieved also using apigenin, an  Erk inhibitor,  
causing a decrease in the TRBP phosphorylation which is pivotal to the maturation of miRNAs
90
. 
Very recently an approach named Inforna was developed for the discovery of small molecules able 
to bind precursors of miRNAs and inhibit their maturation
91
. This approach relies on the 
complementation of bioinformatics and experimental data on the interactions of small molecules 
and annotated RNA motifs, leading to the identification of a) RNA targetable motifs chosen 
between the sites targeted by Drosha or Dicer, b) the lead small molecule and finally  to a 
prevision of the fitness of the interaction. By Inforna, an inhibitor of miR-96 was found and 
validated by a luciferase model system; selectivity of the molecules was found comparable to that 
of an antagomiR. 
Peptide based inhibitors of the maturation of miRNAs have also been tested
92
.   
A recently explored area is represented by the development of oligonucleotides and their 
analogues as inhibitors of biogenesis of miRNAs (Table 3).  Such inhibitors target the apical region 
or the loop  of pri-miRNAs which have been hypothesized to be devoted to recruit trans-acting 
factors as heterogeneous nuclear ribonucleoproteins (hnRNPs)
93
. These factors relax the stem 
loop and help the Drosha mediated cleavage.  LooptomiRs, 2’-OMe oligonucleotides 
complementary to evolutionary conserved terminal loop of pri-miR18a, were found to abolish the 
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processing of miRNAs in vitro by Drosha
94
. RNA aptamers targeting the loop of pri-miR-18a have 
also been obtained and proved to successfully inhibit the maturation and function  of miRNAs
95
. 
 12-mer RNAs complementary to the apical region of the pre-miRNAs, designed to target pre-
miR210 and pre-miR33,  were demonstrated to bind pre-miRNAs and simultaneously sequester 
Dicer, affecting processing of miRNAs
96
; replacement of standard RNA with 2’-OMe units resulted 
in molecules forming with the pre-miRNAs complexes characterized by a higher melting 
temperature and still retaining the ability to inhibit the production of miRNAs. 
Morpholino oligonucleotides  designed to bind the Drosha and Dicer cleavage site on pri-miRNA 
205 and pri-miRNA -375   were demonstrated able to efficiently block the processing of the pri-
miRNA and the consequent maturation and function of miRNA in zebrafish embryos
97
. 
Interestingly the decrease in the expression of miR-375 observed using morpholinos targeting pri-
miRNAs was higher as compared to that obtained using morpholinos targeting mature miRNA-375. 
Peptide Nucleic Acids oligomers conjugated to carrier peptides were designed to target the 
miRNA-210 precursor with the aim to inhibit the maturation of miR-210 
85b
. It was found that such 
molecules down-regulate in a sequence specific fashion miR-210 and also pri-miR-210, leading to 
hypothesize that PNA based molecules strand invade the precursors of miR-210 and therefore 
inhibit their cleavage to mature miR-210. The observation that PNAs affect pri-miR-210 production 
suggests that these molecules  reach the nucleus.   
In a different approach chimeric molecules composed of DNA and LNA, antagomiRzymes,  were 
found to target and cleave pre-miRNAs
98
. These molecules have a central region composed of 15 
DNA bases, whose sequence corresponds to the catalytic core of the  10-23 DNAzyme, which is 
able to cleave at purine-pyrimidine junctions of RNA in the presence of divalent cations. The 
flanking regions of about 7-8 nucleotides, necessary to determine the binding specificity, are 
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complementary to the target pre-miRNA and contain two to four LNAs.  Experiments were carried 
out with molecules targeting the stem of hsa-miR-372 and hsa-miR-373,  in the region 
corresponding to the mature miRNA; in this way, both the precursor and the mature miRNA can 
be cleaved.  AntagomiRzymes containing LNAs were demonstrated to be more effective as 
compared to those composed only by DNAs, although their activity was detected only at high 
concentrations of antagomiRzymes. It has been speculated that targeting of pre-miR loop might 
result in a more efficient inhibitor.  
An alternative strategy to prevent the production of miRNAs relies on the use of proteins as 
transcription activator-like effector nucleases (TALEN). These proteins discovered in the plant 
pathogenic bacteria Xantomonas, contain a DNA binding domain, composed of 33-35 amino acids   
devoted to the recognition of base pairs, and a nuclease to induce DNA cleavage at pre-
determined positions.  Very recent papers report the deletion of miRNA genes by engineered 
endonucleases TALEN and clustered regularly interspaced short palindromic repeats (CRISP)/ 
CRISPR-associated systems in zebrafish
79, 99
. TALENs have also been tested to produce miRNA 
knockout mice
100
. Deletions of chromosomal segments by these strategies may result in the 
deletion of miRNA genes and clusters and can be useful to understand the role of ncRNAs. 
Strategies for the modulation of the function of miRNAs 
The function of miRNAs may be promoted or inhibited. Inhibition may be accomplished using 
synthetic oligonucleotides or vectors encoding inhibitors. One strategy is aimed at sequestering 
the mature miRNAs and preventing their binding to the 3’ UTR regions of the target mRNAs and is 
achieved by synthetic oligonucleotides, or analogues, (the antagomiRs, tiny LNAs). In alternative, 
the function of miRNAs may be blocked using synthetic oligonucleotides complementary to the 
binding site of the miRNAs on the 3’UTR mRNAs, which hinder the binding of miRNAs  to their 
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target RNAs with a consequent inhibition of the translational repression or degradation of the 
mRNA targets. This approach is defined as miRNA masking antisense technology
101
. Synthetic 
tough decoy have also been proposed as inhibitors of miRNAs
102
. A different strategy relies on 
miRNA sponges, transcripts expressed from strong promoters, containing repeated binding sites 
for heptameric seeds, which inhibit miRNAs sharing the same seed
103
. Endogenous miRNA sponges 
include the competing endogenous RNAs (ceRNAs)
43b
, pseudogenes
43a
 and also circular RNAs
104
.  
On the other hand it is possible to increase the amount of miRNAs available by  mimics of miRNAs. 
Examples of inhibitors and mimics of miRNAs are summarized in Table 4. 
Inhibition of miRNAs. The most studied molecules aimed at inhibiting the function of miRNAs are 
named antagomiRs; an antagomiR sequesters the mature miRNA, prevents the interaction of the 
miRNA with its mRNA target and consequently affects the mRNA regulation. The design of an 
efficient antagomiR requires several issues to be addressed
105
: the antagomiR is designed to be 
complementary to the mature miRNA; hybridization of the miRNA has to be effective when the 
miRNA is in a single strand form, or when it is in a duplex with the passenger strand and when it is 
part of the RISC complex. To address all these issues the antagomiR needs to have a binding 
affinity towards the miRNA target high enough to 1) avoid competition with the passenger strand, 
with other natural targets present into the cell, 2) prevent the action of the miRISC helicases which 
could open the miR/antagomiR duplex.  AntagomiRs need to be highly specific, resistant to 
degradation by nucleases and  non toxic. To satisfy all these requirements several oligonucleotide 
analogues have been tested; modifications regard mainly the oligonucleotide backbone, rather 
than the bases. AntagomiRs based on oligonucleotide analogues silence miRNAs by steric blocking, 
but the fate of the antagomiR/miR complexes has been suggested to be dependent on the 
composition of their backbones: high affinity  LNA, 2’-F/2’-MOE, PNA-based  antagomiRs sequester 
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the miRNAs, which do not seem to be degraded; 2’-MOE antagomiRs instead, after binding the 
miRNAs, induce their degradation
106
.  
A considerable amount of work has been reported so far on the use of antagomiRs  and 
importantly few of these are actually in preclinical development. AntagomiRs with different length 
and chemical composition have been explored; we will discuss few examples of antagomiRs, 
grouped based on their chemical modification. 
The first generation of antagomiRs includes oligonucleotides containing  2’-OMe RNA units in their 
central part, as 2’-OMe confers resistance to  endonucleases, phosphorothioates linkages at the 3’ 
and 5’ ends to protect the oligo from exonucleases and finally a 3’ cholesterol modifier (Figure 5) 
to improve the cellular uptake. Such modified oligonucleotides were first tested by Krutzfeldt, who  
reported the efficient and selective inhibition of miR-122 in mice 
107
.  AntagomiRs based on 2’-
OMe were found to sequester and inactivate miR-122 in Huh7 cells stably expressing  the 
genotype 1b strain Hepatitis C Virus-N replicon NNeo/C-5B. 
The antagomiR design reported by Krutzfeldt has found several applications : a 2’-OMe based 
antagomiR against miR-20a has been tested in vivo using the hypoxia-induced mouse model for 
pulmonary hypertension. It was found that inhibition of miR-20a yields the reinstatement of the 
bone morphogenetic protein receptor type II (BMPR2) signalling, whose disregulation is 
considered a hallmark of pulmonary hypertension, and prevents the vascular remodeling 
development
108
.  An antagomiR for miR-17 based on 2’-OMe conjugated to cholesterol was tested 
in vivo in an experimental model of pulmonary hypertension: treatment with the antagomiR 
results in an improvement of the hemodynamic and structural changes caused by hypoxia in mice 
and MCT rats
109
. Recently a 2’-OMe-phosphorothioate-cholesterol conjugated oligonucleotide 
against miR-10b was tested in mice in a mammary carcinoma metastasis model: the antagomiR  
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preferentially targets metastatic cells, where miR-10b is expressed at a higher level; in primary 
tumor cells it inhibits metastasis and causes minimal toxic effects in normal animals
110
.  The 
specificity of antimiR-10b was assessed observing that the levels of  miR-9 and miR-21, which are 
overexpressed in breast cancer, and also the levels of miR10-a,  differing for a single base from the 
mature miR10-b,  were not altered. Another example of antagomiR based on 2’-OMe conjugated 
to cholesterol tested in vivo is represented by the antagomir for miR-24, which causes a reduction 
in the infarction size and improves heart function
111
. 
A 2’-Methoxyethyl (2’-MOE) modified oligonucleotide was tested for the inhibition of miR-21 
signaling in gliomas: this antagomiR induces pro-apoptotic and cell cycle arrest genes, but does not 
change the viability of glioma cells, unlike other  antagomiRs with different backbones
112
. 
2’-Fluoro-2’-methoxyethyl phosphorothioate mixmers have been proposed as antagomiRs: the 2’ F 
is used to improve the binding affinity toward the complementary miRNA, while the MOE and PS 
modifications increase the stability to degradation. An oligomer containing 2’-F/2’-MOE-PS was 
reported as antagomiR for miR33a/b for the treatment of cardiovascular diseases; experiments 
carried out in mice knockout for the low density lipoprotein receptor with atherosclerotic plaques 
demonstrate that the antimiR-33 penetrates the lesions and reaches the plaque macrophages, 
promoting the expression of ATP-binding cassette transporter A1 (ABCA1), which regulates the 
high-density lipoprotein (HDL) synthesis and reverse cholesterol transport, and cholesterol 
removal 
113
. A later study from the same group reports the effect of antimiR-33a/b on African 
green monkeys: systemic delivery of antimiR-33 enhances the expression of ABCA1, promoting an 
increase in the HDL levels in plasma
114
. Expression of genes target of miR-33, including those 
involved in fatty acid oxidation, was found increased, while the expression of genes related to 
fatty acids synthesis was found reduced; interestingly the plasma level of very-low-density-
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lipoproteins (VLDL) associated triglycerides was reduced. These observations encourage the use of 
antimiR-33a/b for the treatment of dyslipidaemias.  
An antagomiR composed of alternated 2’-F and 2’-MOE modified nucleotides with a full 
phospohorothioate backbone has been tested against miR-155, which was found up-regulated in 
Amyotrophic Lateral Sclerosis
115
. In the SOD1
G93A
 rodent model  the antagomiR slowed down the 
disease progression and extended survival. 
The combination of 2’-MOE and 2’-F with a phosphorothioate backbone was also employed to 
produce an antagomiR designed to inhibit miR-27b, a marker of breast cancer metastasis; this was 
shown to bind with higher affinity and specificity than the corresponding 2’-OMe to RNA and to 
efficiently silence miR27-b in a mouse breast tumor model
116
. 
PNAs have been tested as antagomiRs in several cellular assays; they are usually conjugated to 
peptides or bear further backbone modifications to improve their uptake. PNAs conjugated to poly 
lysine targeting miR-122 were reported to inhibit miR-122 and up-regulate its targets in Huh7 cell 
lines and rat hepatocytes. In this cell system the effect of PNA antimiR-122 was found comparable 
to that of a LNA-2’-OMe antagomiR containing phosphorothioates linkages
85a
. Recently a PNA 
antagomiR was tested against miR-690, a miRNA  over-expressed in functional Myeloid-derived 
suppressor cells (MDSCs) induced by delta-9-tetrahydrocannabinol. Inhibition of the miRNA-690 
by the PNA antagomiR results in an increase of the expression of the transcription factor  CCAAT-
enhancer binding protein alpha (C/EBPα), a regulator of cell differentiation. These studies 
highlight the role of miRNAs on the development and function of MSDC, suggesting the possibility 
to modulate the MDSC activity in cancer and inflammatory diseases
117
.  
 Locked Nucleic Acid (LNA) based oligonucleotides have been successfully applied as antagomiRs. 
The LNA antagomiR against miR-195 is in pre-clinical trial for the remodeling of post myocardial 
infarction. miR-195 is a member of the miR-15 family, which contributes to loss of cardiac 
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regenerative capacity
118
; its inhibition is associated to an increased number of mitotic 
cardiomyocytes. Further examples  of LNA based antagomiRs are represented by the antagomiR 
for miR-29 
119
, employed to prevent aortic dilatation, antagomiRs for miR-208 and miR-499 for the 
cure of pathologic cardiac hypertrophy.  
A LNA/DNA phosphorothioate  mixmer, antagomiR  for miR-122, also known as SPC3649 or 
miravirsen developed by Santaris Pharma, was tested on mice and monkeys and demonstrated 
able to efficiently silence miR-122 with a long lasting and reversible decrease in the accumulation 
of plasma cholesterol, without toxicity
82
 . Miravirsen has also been tested on HCV chronically 
infected chimpanzee and found capable of suppressing the HCV viremia, with no evidence of viral 
resistance or side effects
120
. Very recent studies demonstrated that miravirsen inhibits miR-122 
acting on precursors of miRNA
87
. Miravirsen invades the pre-miR122, binding to the 5p  (antisense) 
strand, and inhibits the correct cleavage by Dicer to yield to the production of an extended miRNA; 
also miravirsen binds to the pri-miR, preventing its cleavage by Drosha in the nucleus. These data  
support  the idea, proposed to explain the activity of LIN-28, that the activity of  antagomiRs is 
related to their ability to bind to precursors, inhibiting their biogenesis. 
The activity of miRNAs may also be temporally controlled by photocaged antisense 
oligonucleotides; 2’-OMe oligonucleotides were tested in a C.elegans model, and for this they are 
named cantimirs. These molecules are composed of an antagomiR strand connected through a 
bifunctional coumarine linker (Figure 5) to a “blocking” strand; after photolysis initiated by 
irradiation with light at 365 nm the linker is cleaved, the blocking strand is released and the 
antagomiR may exert its function
121
. 
Tiny LNAs, 8-mers targeting the seed region of miRNAs were introduced by Patrick in 2010
122
 to 
inhibit miR-21; these studies suggested that this miR is not involved in cardiac hypertrophy or 
fibrosis, although contradicting results have been reported
123
. These oligomers have a fully 
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phosphorothioate backbone and have been employed later in applications aimed at inhibiting 
miRNAs of the same family, sharing the same seed. Targeting of miR-122 in a mouse liver by 
phosphorothioate tiny LNAs resulted in silencing of miR-122, de-repression of the targets of 
miRNA, with effects in vivo comparable to those obtained using a 15-mer LNA antimiR-122
124
. The 
application of a tiny antiseed with a phosphodiester bond instead of phosphorothioate bond had 
no effect on miR-122 and its targets, highlighting the importance of phosphodiester modification 
on the delivery and activity of the tiny antiseed.  A tiny LNA was successfully employed in a mouse 
model of Sonic Hedgegog medulloblastoma to inhibit the miR 17-92 cluster; treatment of mice 
with this antiseed results in a reduction of the tumor growth and prolonged survival of mice
125
.  A 
seed targeting LNA has recently been employed in non-human primates for the inhibition of miR-
33, a regulator of cholesterol/lipid homeostasis. In obese and insulin resistant non-human 
primates, inhibition of miR-33 by subcutaneously delivered tiny LNA yields de-repression of miR-33 
targets and increase of the high density lipoprotein cholesterol
126
. 
An alternative approach to antagomiRs was proposed by Haraguchi in 2012, based on the use of 
synthetic 2’-OMe RNA duplexes, named synthetic tough decoys (S-TuD), containing binding sites 
(MBSs) for miRNA flanked at both ends by rigid stems
127
. The S-TuD design derives from the 
previously reported Tough Decoy RNAs, which have been reported to produce a long-term 
suppression of specific miRNA activity when expressed from lentivirus vectors in mammalian 
cells
102
. S-TuDs against miR-21, miR-200c and miR-106b transfected into HCT-116 cells silence the 
miRs with high efficiency. Experiments carried out with S TuD against miR-200c demonstrated that 
the inhibitory effect after a single transfection is long lasting and is retained even when the 
concentration is very low. The effects of S TuDs on silencing  miRNAs sharing the same seed seem 
undetectable. 
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Inhibition of the function of miRNAs by miRNA masking oligonucleotides, which interfere in the 
miRNAs/mRNAs interactions has been reported. Experiments carried out in zebrafish embryo 
demonstrate that 25-mer morpholino oligonucleotides complementary to the sqr or lft  3’UTR 
regions, which are targets of miR-430, inhibit the repression of the sqt-GFP reporter, which is 
normally induced by miR-430
101a
. 
 
Replacement of miRNAs. Sometimes restoring the function of miRNAs in cells might have 
therapeutic applications, for example when miRNAs silence unwanted or harmful genes, as when 
miRNAs act as tumor suppressors. The amount of miRNAs in cells may be restored  using mimics of 
miRNAs or small molecules. As an example of small molecule we report the case of the 
antibacterial compound enoxacin, which is able to stimulate the expression of microRNAs tumor 
suppressor by enhancing microRNAs biogenesis machinery
128
; however this approach  is not 
specific toward a single miRNA, unlike oligonucleotide-based approaches. 
The function of miRNAs may be restored by mimics of miRNA, synthetic double stranded RNAs, 
which have one strand of the same sequence as endogeneous guide miRNA and the passenger 
strand either perfectly complementary or with mismatches. The guide is usually designed so that 
its 5’ end is partially complementary to the sequence of the 3’ UTR unique to the target gene. As 
siRNAs, mimics of miRNAs are processed by the RISC complex; while siRNAs are usually employed 
to silence a single mRNA inducing the degradation of its target,  mimics target several transcripts, 
and potentially may regulate several genes. 
Most of the studies are carried out with standard RNA duplexes, but there are also cases in which 
modified molecules are tested. For example hindered substituents on the bases, as propyl and 
cyclopentyl
78c
 (Figure 4), which project in the minor groove, have been introduced in  with the aim 
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to reduce off target effects such as those derived from double-stranded RNA binding motifs and 
TLR-mediated immunostimulatory effects. Recent experiments carried out in peripheral blood 
mononuclear cell with mimics of miRNAs, aimed at restoring the activity of miR-122, 
demonstrated that cyclopentyl-guanines at positions 9 and 16 of the guide strand, in combination 
with cyclopentyl 2-aminopurine at positions 13 and 15 of the passenger strand, reduce the 
immunostimulatory activity of molecules, drastically decreasing the TNF-alpha levels
78c
. 
Interestingly some mimics of miRs are in clinical trials, as the mimics of miR-34 and let-7, both 
employed for the treatment of cancer. miR-34 antagonizes several oncogenic processes: it 
controls cell proliferation activating tumor suppressors pathways, inhibits cancer stem cells, which 
represent the seed of the tumor, metastasis and chemoresistance
129
. A liposomal formulation of a 
miR-34a mimic , named MRX34, is now in  clinical trials at Mirna therapeutics Inc. for the 
treatment of patients with unresectable primary liver cancer or metastatic cancer with liver 
involvement (http://www.mirnarx.com/). The involvement of miR-34a in different cellular 
pathways led to hypothesize that miR-34a may act in synergy with conventional cytotoxic drugs: 
the combination of erlotinib, a tyrosin kinase inhibitor effective in a limited number of cases on 
non-small cell lung cancer, and a miR-34a mimic was tested in a panel of hepatocellular carcinoma 
cells (which are refractive to erlotinib)
130
. Interestingly, the drugs exert synergistic effect also on 
cells not sensitive to erlotinib. 
Another example of mimic of miRNA, potential candidate as drug for lung cancer, is let-7, a tumor 
suppressor targeting a variety of oncogenes. Administration of let-7 mimic prior to implantation of 
the tumor xenograft in mice suppresses tumor formation while blocks tumor growth when 
injected into tumors developed prior to the treatment
131
. Experiments carried out in mice 
expressing an inducible mutant of the oncogene K-RAS, responsible for the formation of the non-
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small cell lung carcinoma (NSCLC), demonstrate that intravenous delivery of let-7 inhibits the 
formation of lung tumors
132
. 
In alternative, single stranded RNA mimics are employed as mimics of miRNAs; few studies on 
single stranded modified RNAs, ss-siRNAs, have been reported so far. ss-siRNAs are introduced as 
single strands and are designed for a seed-based recognition, as miRNAs. As siRNAs, ss-siRNAs are 
involved in the RNAi pathway, requiring Ago 2 for activity. Pioneering studies have been carried 
out by Chorn et al, who have tested 5’ phosphorylated miR-124 mimics containing 2’-F and 2’-
OMe
133
. The authors found that the single stranded mimics containing 2’-F nucleotides with a 
length of 19-22 nucleotides, were the most active in the inhibition of the target of the miR CD164 
in HT116 cells. Substitution in position 2’ of one F with one OMe caused a decrease in the activity 
of the mimic. Experiments carried out randomizing the 3’ end bases of the mimic demonstrated 
that cassettes with a high percentage of pyrimidine perform better in the inhibition of the targets 
of the mimic as compared to cassettes with  high purine content. 
 A very wide study has been proposed by Lima et al on the modifications which improve stability, 
pharmacokinetics and efficiency of ss-siRNAs
134
. Substitution of the 5’-phosphate by a stable 5’-E-
vinylphosphate (VP) (Figure 5) increases the metabolic stability of the ss-siRNA. Structure-activity 
studies in which the chemical modifications of the RNA backbone and the Ago2 activity were 
evaluated, allowed to develop an active chimeric molecule composed of 2’-F phosphorothioates -
2’OMe phosphodiesters alternated nucleotides, a 5’ VP followed by a 2’O-methoxyethyl 
nucleotide, and two adenosines 2’-Omethoxyethyl at the 3’ end. Modified ss-siRNAs targeting 
Factor VII and ApoCIII mRNA showed a 50% reduction of the targets in the liver, but not of the off 
targets. 
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ss-siRNAs were successfully tested in vivo, in the mouse central nervous system, to silence the 
mutant huntingtin and have proven to perform more efficiently than the ds-siRNA counterparts
135
.  
RNAi for functional studies on ncRNAs 
RNA interference (RNAi) is a naturally occurring pathway initiated by dsRNAs aimed at protecting 
the genome from the invasion of viruses and transposon. The RNAi machinery can be triggered by 
21 nts duplexes directly introduced into cells (siRNAs) or engineered to be expressed in cells as 
short hairpins (shRNAs), which are then processed to siRNAs. siRNAs bind to the RISC complex 
which separates the siRNAs in two strands: the passenger strand, which is degraded and the guide 
strand which is carried from the RISC to its target mRNA, which will be cleaved. The introduction 
of synthetic siRNAs, as described by Zamore in 2000, is the methodology of choice for gene 
silencing in different experimental systems
4a
. siRNA duplexes have been modified in order to 
improve their silencing activity, which depends upon their stability to degradation, affinity and 
specificity of binding toward Ago2 and the target mRNA
136
 (Table 5). Many companies started 
clinical trials using siRNAs for the cure of a number of diseases ranging from cancer to viral 
infections to hypercholesterolemia
137
. Although the exact composition of the drugs is not known, 
it appears that the main efforts in this field are devoted to the development of platforms for the 
targeted delivery of siRNAs, showing no accumulation in the target tissues, no sensitization during 
chronic dosing and durable knockdown of the target genes. 
Interestingly siRNAs are also commonly employed in loss of function studies, aimed at 
understanding the biological role of ncRNAs. Few examples are described here. 
siRNAs have been employed to unravel the function of the lncRNA AK139328, expressed at very 
high levels in normal mouse liver. AK139328 knockdown improved the ischemia/reperfusion injury 
in mouse livers, suggesting that this lncRNA may be a novel target to treat ischemia/reperfusion 
injuries
138
. 
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The role of the lncRNA HOTAIR, deregulated in breast cancer progression, was discovered after 
HOTAIR depletion experiments by siRNAs in MCF7 cell
139
. These and other experiments suggested 
that HOTAIR promotes invasiveness in breast carcinoma cells. 
In another example siRNAs were employed to target the lncRNA Fork head box C1 upstream 
transcript (FOXCUT), which was found overexpressed in oral squamous cell carcinoma: FOXCUT 
knockdown inhibited cell proliferation and migration and allowed to understand the positive 
correlation between the FOXC1 gene and the upstream transcript FOXCUT expression
140
. Finally 
we cite the example of siRNAs used to silence H19 RNA, an oncogenic lncRNA characterized in 
breast and colon cancer; H19 depletion by siRNAs resulted in suppression of U87 and U251 cell 
invasiveness and attenuation of migration
141
. 
 
Modulation of the expression/function of long non coding RNAs  
 The knowledge we have at this time of the long non coding RNA world reveals that we are facing a 
very heterogeneous group of molecules, whose interactors have not yet been precisely defined, 
although some functions have been discovered, as described earlier. Interestingly, lncRNAs have 
already been recognized as unique targets for drugs as they offer the possibility of targeting a 
single location in the genome. The relationship emerging between the misregulation of the  
expression of ncRNAs and diseases also encourages studies aimed at discovering new tools to 
modulate their expression. The length of lncRNAs let us think of extensive secondary structures; 
therefore it is reasonable to suppose that efficient targeting of ncRNAs may be achieved by 
molecules with high affinity toward RNA, able to disrupt such structures. Experiments aimed at 
interfering with the expression of lncRNAs have been carried out in most cases with shRNAs and 
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siRNAs, with the aim to understand their function
139
.  Molecules employed for the targeting of 
lncRNAs are summarized in Table 6. 
Single stranded oligonucleotide analogues have been used to target Natural Antisense Transcripts 
(NATs) to achieve the up-regulation of the corresponding protein. A recent paper by Modarresi  
reports that the inhibition of the NAT brain derived neurotrophic factor antisense transcript 
(BDNF-AS) by single stranded oligonucleotides (antagoNATs) results in the transient and reversible 
up-regulation of locus-specific gene expression
37
. The antagoNATs are 14-mers containing 
mixtures of 2’-OMe RNAs and LNAs; LNAs cap the oligonucleotide 3’ and 5’ ends and replace three 
more 2’-OMe bases within the sequence. BDNF-AS represses BDNF; inhibition of BDNF-AS causes 
the up-regulation of the BDNF mRNA transcript, alteration of the chromatin marks at the BDNF 
locus, increased protein levels, induction of neuronal outgrowth and differentiation in vitro and in 
vivo.  
The antagoNAT strategy was applied also to inhibit the apolipoprotein 1-antisense, APOA1-AS
38
. 
APOA1-AS is a negative transcriptional regulator of the apolipoprotein 1 (APOA1) in vitro and in 
vivo, which modulates different histone methylation patterns. Phosphorothioates designed to 
cover all the APOA1-AS sequence were tested in humans and African green monkeys cells; active 
antagoNATs were found to cause the up-regulation of APOA1 mRNA. One 12-mer gapmer 
composed of two LNA nucleotides at the 5’ end and three LNA nucleotides at the 3’ end was 
injected intravenously into monkeys: the effect of this antagoNAT was an increase in the APOA1 
mRNA expression, as judged by RT-PCR analyses of liver biopsies and an increase in the APOA1 
circulating protein. These experiments demonstrate the effectiveness of antagoNATs in a primate 
model, suggesting the applicability of such strategy to induce gene up-regulation for a therapeutic 
purpose. 
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Morpholino oligonucleotides were employed to target the recently identified HELLP lincRNA
142
. 
This long intergenic transcript is expressed in the placental extravillous trophoblast and is 
associated to HELLP syndrome, a disease associated to pregnancy inducing hemolysis, elevated 
liver enzymes and low platelets in the mother. Morpholinos targeting potential mutation site 
identified in HELLP families were demonstrated to reduce the invasion capacity of the 
trophoblasts. 
LNAs have been used to knockdown eRNAs; it was found that LNAs caused the inhibition of 
induction of either the eRNA and the adjacent coding gene. It is therefore possible, by knocking 
down eRNAs, to modulate enhancers and related genes in a cell specific fashion
143
.  
Inhibition of the function of long non-coding RNAs by modified oligonucleotides may also be 
achieved with the aim to investigate pharmacological properties of modified oligonucleotides. The 
noncoding RNA gene metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was 
employed as a target to study  biodistribution, pharmacokinetic of modified oligonucleotides
144
. A 
20-mer chimeric phosphorothioate oligonucleotide modified by 5-mer 2’-MOE at the 3’ and 5’ 
ends was tested in murine models while  chimeric phosphorothioate oligonucleotides modified by 
ethyl bicyclic nucleic acid (cEt) in the three bases located at the 3’ and 5’ ends were tested in 
murine and monkey models.  The concentrations of the oligonucleotide analogues were evaluated 
in different tissues and found to correlate with the MALAT1 knockdown; in general accumulation 
was higher in mice than in monkey organs and, accordingly, knockdown of MALAT1 was found 
more effective in mice than in monkeys. Liver was confirmed to be the primary target organ of the 
oligonucleotides systemically administered. 16-mer cEt was found more potent as compared to 
the 20-mer MOE in down-regulating MALAT1, although equally distributed across different species 
and organs.  
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With the aim to identify the functional region of the lncRNA Xist, Peptide Nucleic Acids oligomers 
have been employed in mapping experiments
145
. The technology named Peptide Nucleic Acid- 
Interference Mapping (P-IMP) based on the use of PNA oligomers conjugated to the carrier 
peptide transportan complementary to different regions of the first exon of Xist allowed the 
identification of a 19 nucleobases oligomer able to disrupt the binding of Xist to the X-
chromosome, inhibiting the formation of Xi. These experiments demonstrate that Xist is organized 
in domains and that it exerts its function after binding to the X-chromosome; the Xist region 
responsible for the X-chromosome binding was also identified. 
The function of long non coding RNAs was investigated by nuclease-induced segmental deletions 
of the corresponding genes. A recent paper reports the use of Zinc Finger nuclease and TALEN   
for the deletion of a lincRNA gene in zebrafish
146
. In studies on the function of MALAT1, Zinc Finger 
Nucleases were employed to silence its expression in human tumor cell; these studies revealed 
that the loss of the lncRNA is compatible with life and development
147
. 
 
More applications of oligonucleotide analogues  
Another aspect which deserves to be at least cited is the use of oligonucleotide analogues in 
studies devoted to the detection of ncRNAs and their targets. Peptide Nucleic Acids, for example, 
were employed to build molecular beacons for the detection of the long non coding Colon Cancer 
Associated Transcript 1 (CCAT1)
148
. The PNAs conjugated to poly-lysine and to the transdermal cell 
penetrating peptide contained as surrogate base the so called FIT probe, which acts as a light-up 
probe, allowing the imaging of CCAT1 in either cell lines and human biopsies. A little investigated 
but nevertheless interesting field is that of the imaging of nucleic acids using metal complexes; in 
fact, photophysical properties of metal complexes may be fine-tuned changing the metal ligands. 
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Metal complexes of 
64
Cu and 
99
Tc conjugated to PNAs were applied to obtain scintigraphic imaging 
by PET and MRI of oncogene mRNA in tumors
149
. A paper from Mari et al proposed the use of 
luminescent rhenium complexes conjugated to PNA as tools for the detection of nucleic acids in 
cells; these complexes bearing bypiridine ligands were tested in HEK-293 cells and were 
demonstrated to possess good photoluminescence quantum yields
150
. The methodologies 
described may reasonably be applied to the imaging of ncRNAs in cells. 
RNA oligomers modified by photo-activable moieties were recently described as tools to capture 
targets of miRNAs: a psoralen residue was incorporated into a biotinylated miRNA; upon 
irradiation the modified miRNA cross links to the target mRNA, which is isolated by biotin-
streptavidin affinity column chromatography
151
. A similar application is described with RNA 
nucleotides bearing a diazirine containing nucleoside
152
. 
 
Conclusions and perspectives 
The recent findings on the functions of ncRNAs and on the networks they are involved in have 
substantially widened our prospects on gene regulation: ncRNAs are involved in RNA editing, work 
as scaffolds to help the assembly of multiple proteins, are gene repressors and recruit 
transcriptional regulators. Likely, many other biological activities will be discovered in the next 
future. The multiple functions discovered for ncRNAs highlighted new potential targets of 
pharmacological relevance; interestingly many of these functions are exploited through base 
pairing. The modulation of the expression of short and long ncRNAs  by synthetic oligonucleotides 
appears therefore as a promising strategy to cure different diseases, from cancer to cardiovascular 
diseases. Although a detailed understanding of the mechanism of action of ncRNAs is not available 
yet, advanced studies in the field of short ncRNAs led to a number of clinical trials with either 
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siRNAs, antagomiRs or miR mimics in a reduced time span.  The design of unmodified 
oligonucleotides for siRNA, shRNA and antagomiR applications is aided by bioinformatics 
platforms, based on the combination of known or predicted thermodynamic parameters referred 
to the stability of siRNA and miRNAs’ secondary structure,   accessibility of the targets predictions 
and experimental data related to the activity of siRNAs/miRNAs.  Unfortunately it is not as easy to 
design modified oligonucleotides and to predict how chemical modifications affect the stability 
and structure of the mimics and which modification will increase the potency of our molecules. 
Thermodynamic parameters may be obtained for 2’-OMe RNA/RNA and LNA-2’-OMe RNA/RNA 
duplexes using calculators developed by Kierzek et al, (http://rnachemlab.ibch.poznan.pl/) based 
on studies of the thermodynamic properties of synthetic modified duplexes. The next step will be 
that of performing structural studies of complexes formed by the oligonucleotides (or analogues) 
and ncRNAs, combining the structural and activity data available to obtain new bioinformatics 
tools useful to predict stable and bioactive molecules.  The combination of structural data, 
biological activity data as derived from clinical trials and availability of thermodynamic predictions 
tools will contribute to the development of safe and potent oligonucleotides based drugs. 
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Table 1. Small RNA classes 
  
Name (abbreviation)    length, mechanism of action and function 
microRNAs (miRNA)   ∼19-25 nts, are produced by Dicer mediated cleavage of double- stranded portion 
of precursors of miRNAs. Associate with the miRISC complex and modulate, at the 
post-trascriptional level, protein expression by partial complementary base-
pairing with target mRNAs; affect translation and  stability of mRNAs  . 
Mirtrons ~22 nts, belong to the  splicing-derived miRNAs that comprise also 5’-tailed 
mirtrons,  3’-tailed mirtrons and sintroms. Function as miRNAs. 
microRNA-offset RNAs 
(moRNAs) 
~ 20 nts, are produced by the hairpin precursor of miRNAs . So far, the knowledge 
on their possible functions is still fragmentary. 
Piwi-interacting RNAs 
(piRNAs) 
∼26-31 nts, are produced by a Dicer independent mechanism. They exclusively 
bind to the Piwi subfamily of the Argonaute proteins, are essential in the 
development of germ cells and regulate transposon activity. 
Promoter-associated 
short RNAs (PASRs) 
∼20-200 nts, are produced by a Dicer independent mechanism. Their localization 
at genomic level coincides with the 5’ end of transcription start sites of both 
coding and non-coding genes. A role in the regulation of gene expression has been 
hypothesized. 
QDE-2 interacting 
small RNAs (qiRNAs)   
 
∼20-21 nts, in their mature form interact with QDE2, a member of the Argonaute 
protein family.  Their role in the DNA damage response (DDR) remains to be 
clarified . 
Small interfering RNA 
(siRNAs)  
 
∼20-24 nts, produced by Dicer mediated cleavage of double-stranded duplexes. 
Form complexes with Argonaute proteins; by fully complementarity with their 
targets modulate  gene expression, are involved in transposon control. siRNAs are 
involved in the immune response either in plants and in mammalian. 
Small nucleolar RNAs 
(snoRNAs) 
 
∼60-300 nts, are produced by a Dicer independent mechanism. Members of the 
larger family of snoRNAs, are localized to the nucleolus . Are involved in 
pseudouridylation and ribosomal RNA modifications. 
Small-viral RNAs 
(svRNAs)  
∼ 22–27 nts, derive from viruses,   can control the viral switch between 
transcription and replication. In particular, svRNAs are detectable during 
replication of various influenza A viruses, their expression correlates with the 
accumulation of viral genomic RNA (vRNA). 
Sno-derived RNAs 
(sdRNAs)  
∼20-24 nts, are produced by Dicer cleavage of longer precursors, associate with 
Ago2. Possess regulatory functions, being involved in gene silencing. 
Splice junction 
associated RNAs 
(spliRNAs) 
∼17- 18 nts, hypothesized to be generated by a RNAP II dependent mechanism, 
are  involved in the post-transcriptional gene silencing. 
Telomere small RNAs 
(tel-sRNAs) 
∼24 nts, are produced by a Dicer independent mechanism. Are involved in the 
establishment and maintenance of heterochromatin structures. 
Trascription initiation 
RNAs (tiRNAs) 
 
∼18 nts, are produced by a Dicer independent mechanism. Typically derived from 
sequences localized immediately downstream of transcription initiation sites, 
have been hypothesized to be involved in the transcription. 
Transcription start 
site–associated RNA 
(TSSa RNAs)   
 
∼ 20-90 nts, flank active promoters, probably regulate the maintenance of 
transcription. 
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Table 2. Long ncRNA classes 
Name (abbreviation) length, mechanism of action and function 
Antisense Non-coding 
RNA in the INK4 Locus 
(ANRIL) 
Transcribed by RNA pol II, has alternatively spliced isoforms, the unspliced 
transcript is 34.8 kb termed p15AS. Plays an important role in cell cycle control, 
cell senescence, stem cell renewal and apoptosis and has been associated with a 
range of human diseases including cancer. 
Competing 
endogenous RNAs 
(ceRNAs):  
 Natural decoys for microRNAs. The majority of validated ceRNAs are mRNAs, also 
some transcripts of lncRNAs have been described to have ceRNA activity. They  
play important roles in physiological and pathological processes, such as 
development and cancer. 
Circular RNAs 
(circRNAs) 
Endogenous RNAs, arising  from  a 3′–5′ ligation of both ends of a linear RNA 
strand, are characterized by multiply repeated miRNA binding sites, that can serve 
as sponge for  miRNAs. Possess interesting   properties as  high cellular resistance 
to exonuclease   digestion, and lack of a poly-A tail that would avoid miRNA-
mediated   destabilisation after the  binding . Mammalian brain tissues appear to 
be enriched in ciRS-7 , a circRNA that contains multiple, tandem sequences for 
miR-7. 
Enhancer RNAs 
(eRNAs):    
≈2- kb, involved in development and differentiation, are important regulators of 
their neighboring protein-coding genes. 
 
Homeobox (HOX) 
transcript antisense 
RNA (HOTAIR) :  
2.3kb, is an intergenic ncRNA, spliced and polyadenylated; it has been found  
associated with the mammalian polycomb repressive complex 2 (PRC2). It is 
involved in primary and metastatic breast cancer. 
KCNQ1 overlapping 
transcript 1 
(KCNQ1OT1):  
91 kb, is an imprinting lncRNA, unspliced and polyadenylated transcript found in 
the nuclear compartment. It is transcribed in the antisense direction to Kcnq1 
gene, it is important for bidirectional silencing of genes in the Kcnq1 domain and 
regulates the expression in cis of neighboring genes. 
Metastasis-associated 
lung carcinoma 
transcript 1 (MALAT1)  
About 7 kb, localized in nuclear speckles, is  processed by RNaseP and RNaseZ to 
generate the small ncRNA mascRNA, which is then exported to the cytoplasm. 
The larger MALAT1 RNA seems to have a role in regulating alternative splicing 
machinery. Studies have demonstrated implication of MALAT1in multiple cancers. 
Natural antisense 
transcripts (NATs) 
 Have partial or full sequence complementarity to other transcripts. Although the 
function of the majority of NATs is still unknown, experimental evidences suggest 
that they can be subdivided in  cis- and trans NATs . They are involved in a broad 
range of gene regulatory events. 
Promoter upstream 
transcripts (PROMPTs)  
200-600 nts, are produced immediately upstream of TSS . Are transcribed in both 
sense and antisense direction respect to the TSS of gene. Their function is largely 
unknown. 
Ultraconserved RNAs 
(T- UCRs) 
 
 200-3000 nts,  are transcription products of UCRs, localized in genomic regions, 
absolutely conserved (100% identity with no insertions or deletions) between 
orthologous regions of the human, rat, and mouse genomes. Their function are 
still undefined but evidence supports their modulation on gene expression that 
includes  an antisense inhibitory role for other ncRNAs or protein coding genes, or 
a role as enhancer of gene expression, or as a sponge for microRNAs. 
X-inactive specific 
transcript RNA (XIST) 
 17 kb in mouse and 19 kb in human,  is a  polyadenylated long ncRNA that plays a 
critical role in X-chromosome inactivation. 
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Table 3. Examples of oligonucleotide analogues inhibitors of the maturation of miRNAs 
 
 
  
Name Function Modification/architecture Mechanism of action 
LooptomiR Inhibition of the  
biogenesis of miRNAs  
2’-OMe/ss Bind to  pri-mi loop, abolishing 
Drosha activity 
Antipre-miR Inhibition of the  
biogenesis of miRNAs 
PNA/ss Bind to pre-miR, preventing its 
processing 
Antipri-miR Inhibition of the  
biogenesis of miRNAs 
Morpholino/ss Bind the pri-miR, preventing 
its processing 
AntagomiRzyme Inhibition of the  
biogenesis of miRNAs 
DNA,LNA/ss Bind and cleave the pre-miR 
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Table 4. Examples of oligonucleotide analogues modulators of the function of miRNAs  
 
Name Function Modification/architecture Mechanism of action 
AntagomiRs  Inhibit the function 
of miRNAs  
LNA, 2’-F, 2’-OMe, 2’-MOE, PNA, 
PS, cholesterol  /ss 
Sequester the mature miRNAs 
and prevent the interaction of 
miRNAs and mRNAs  
Tiny LNAs Inhibit the function 
of miRs sharing the 
same seed 
LNA-PS/ss Bind the seed region of miRNAs 
and prevent interactions of 
miRNAs and mRNAs  
CantimiRs Controlled Inhibition 
of the  function of 
miRNA  
2’-OMe (stems)-coumarin 
(loop)/asymmetric stem loop 
See AntagomiRs 
S-TUDs Inhibit the function 
of miRNAs  
2’-OMe/ds Bind to miRNAs 
miR-masks Inhibit the function 
of miRNAs 
Morpholino/ss Bind the 3’UTR mRNA regions 
which are occupied by miRs and 
prevent interactions of miRNAs 
and mRNAs   
miRNA 
mimics 
Enhance the  activity 
of miRNAs - regulate 
several transcripts 
LNA, 2’-F, 2’-OMe,PS /ds Are incorporated into the RISC 
and do not induce degradation 
of mRNAs  
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Table 5. Examples of oligonucleotide analogues for gene silencing 
Name Function Modification/architecture Mechanism of action 
siRNAs Silence 
potentially  a 
single gene 
LNA, 2’-F, 2’-OMe, 2’-
MOE, PNA, PS, allyl, 
cholesterol/ds 
Are incorporated into the RISC and 
induce mRNA degradation 
ss-siRNAs Silence 
potentially  a 
single gene 
2’-F, 2’-OMe , PS,  5’ 
phosphate, 5’-E-
vinylphosphate/ss 
Are incorporated into the RISC and 
bind the target mRNA by their 
seed 
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Table 6. Examples of  oligonucleotide analogues as modulators of the function of lncRNA  
 
Name Function Modification/architecture Mechanism of action 
antagoNAT Up-regulation  of 
locus-specific 
gene expression 
2’-OMe, LNA, PS/ss Bind Natural antisense 
transcripts 
Other Antisenses 
to lncRNAs 
Inhibition of lnc 
(linc, MALAT1) 
Morpholino, 2’-MOE, PS, 
cEt/ss 
Bind selected lncRNAs, inhibiting 
their function 
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Table 7. Examples of  non oligonucleotidic molecules as modulators of the function of ncRNAs 
 
Name Function Mechanism of action 
Small molecules (e.g. 
aminoglycosides) 
Inhibition of maturation 
of miRNAs 
Bind to Drosha or Dicer sites on pre-miRNAs 
peptoids Inhibition of maturation 
of miRNAs 
Bind to loops of pre-miRs 
TALEN Inhibition of production 
of miRNAs  
Deletion of ncRNA genes 
CRISPR-associated (Cas) Inhibition of production 
of miRNAs  
Deletion of miRNA genes 
Zinc Finger Nuclease Inhibition of production 
of miRNAs  
Deletion of lncRNA genes 
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Legends to Figures 
Figure 1. Selected examples of clinical applications of antagomiRs of: A: miR 92-a, which targets 
Janus kinase 1 (Jak 1) and integrin α5 (Itgα5), results in proangiogenic effects
153
; B: miR-21, which 
binds to Spry1, a negative regulator of the MAP kinase signaling in cardiac fibroblasts, reverting 
interstitial fibrosis and alleviating cardiac disfunction
123a
; C: miR-33a, which targets the adenosine 
triphosphate-binding cassette transporter A1 (ABCA1), acting on cholesterol transport
114
; D: miR-
122, causes a reduction in the HCV RNA replication
82
. 
 
Figure 2. Selected examples of application of siRNAs for the knockdown of: A: B-cell 
CLL/lymphoma 2 (BCL-2), an antiapoptotic protein overexpressed in Chronic lymphocytic leukemia 
(CLL)
154
; B: protein kinase N3 (PKN3),  resulting in the inhibition of tumor progression and 
metastasis formation in patients with advanced solid tumors
155
; C: MALAT and HOTAIR which 
results in the inhibition of invasion and migration of lung metastases
40139
; D:  polo-like kinase 1 
(PLK-1) which inhibits liver metastases progression
156
. 
Figure 3. Representation of the chemical structure of oligonucleotide analogues with modification 
on the backbone. B: nucleobase. 
Figure 4. Representation of the chemical structure of the modified bases. R= ribose. 
Figure 5. Representation of the chemical structure of the “end capping” tools. 
Figure 6. Representation of two conformations assumed by the sugar rings in oligonucleotides. 
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Figure 1. Selected examples of clinical applications of antagomiRs of: A: miR 92-a, which targets Janus 
kinase 1 (Jak 1) and integrin α5 (Itgα5), results in proangiogenic effects153; B: miR-21, which binds to 
Spry1, a negative regulator of the MAP kinase signaling in cardiac fibroblasts, reverting interstitial fibrosis 
and alleviating cardiac disfunction123a; C: miR-33a, which targets the adenosine triphosphate-binding 
cassette transporter A1 (ABCA1), acting on cholesterol transport114; D: miR-122, causes a reduction on the 
HCV RNA replication82.  
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Figure 2. Selected examples of application of siRNAs for the knockdown of: A: B-cell CLL/lymphoma 2 (BCL-
2), an antiapoptotic protein overexpressed in Chronic lymphocytic leukemia (CLL)154; B: protein kinase N3 
(PKN3),  resulting in the inhibition of tumor progression and metastasis formation in patients with advanced 
solid tumors155; C: MALAT and HOTAIR which results in the inhibition of invasion and migration of lung 
metastases40139; D: the polo-like kinase 1 (PLK-1) inhibits liver metastases progression156.  
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Figure 3. Representation of the chemical structure of oligonucleotide analogues with modification on the 
backbone. B: nucleobase.  
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Figure 4. Representation of the chemical structure of the modified bases. R= ribose.  
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Figure 5. Representation of the chemical structure of the “end capping” tools.  
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Figure 6. Representation of two conformations assumed by the sugar rings in oligonucleotides.  
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